Recent Updates
Recently added Catalysts
RADX Neutral Sentiment Score: 50/100

Change of Director’s Interest Notice – RC

Wednesday, November 22, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced a change in director's interest, alongside various updates regarding their clinical studies and research initiatives. The company is actively involved in multiple programs, including the Phase 1/2a clinical study of BetaBart (RV-01). Recent announcements also highlight the appointment of Dr. Oliver Sartor to their Scientific Advisory Board.

Market Sentiment Analysis

Full Press Release Details

• Announcements
• November 22, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• September 28, 2023
• Announcements
• October 23, 2024
• Announcements
• January 5, 2024
• Announcements
• December 13, 2021

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research
Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart clinical study Dr. Oliver Sartor
Last updated: Nov 22, 2023